Relationship between cytochrome P450 2C19 gene polymorphism and primary hepatocellular carcinoma

Chinese Journal of Gastroenterology

Volumn 13, Issue 1, 2008, Pages 39-41

  Jiang, Wen ^a   Shao, Jianguo ^a   Lu, Jianrong ^a  

^a Third People's Hospital of Nantong   (China)

Author keywords

Cytochrome P 450 enzyme system; Liver neoplasms; Polymorphism, genetic

Indexed keywords

EID: 80054011310     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 1994, 33 (7): 1743-1752. (Pubitemid 24089701)
2. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet, 2005, 20 (3): 153-167.
3. Chen S, Chou WH, Blouin RA, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther, 1996, 60 (5): 522-534. (Pubitemid 26414088)
4. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem, 1994, 269 (22): 15419-15422.
5. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol, 1994, 46 (4): 594-598. (Pubitemid 24334747)
6. Wrighton SA, Stevens JC, Becker GW, et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys, 1993, 306 (1): 240-245. (Pubitemid 23291309)